AhmedSawasMD

Hematologic Oncology

Instructor, Medicine, Columbia University College of Physicians and Surg

Overview of Dr. Sawas

Dr. Ahmed Sawas is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in cutaneous t-cell lymphoma of the penis, cold agglutinin disease, cold autoimmune hemolytic anemia, and oropharyngeal lymphoma. He has more than 30 publications and over 500 citings.

Office
161 Fort Washington Ave
New York, NY 10032
Book by Phone+1(218) 729-2153

Education & Training

Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Westchester Medical CenterResidency, Internal Medicine, 2006 - 2009
State University of New York Downstate Medical Center College of MedicineClass of 2006

Certifications & Licensure

NY State Medical License 2009 - 2025

Clinical Trials

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Start of enrollment: 2013 Mar 01
Withdrawn
Phase 1
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) Start of enrollment: 2014 Mar 05
Completed
Phase 2
AFM13 in Relapsed/Refractory Cutaneous Lymphomas Start of enrollment: 2017 Jul 17
Completed
Phase 1, Phase 2
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides Start of enrollment: 2019 Nov 13
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas.
Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalia Mikhailova, Dejan Radeski
Clinical Cancer Research. 2024-11-12
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium.
Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean Michael McCabe
Blood Advances. 2024-10-31
1 citations
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-...
Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Brian Estrella
Leukemia & Lymphoma. 2024-06-01

Journal Articles

Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma
Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Abstracts/Posters

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Ahmed Sawas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

$Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-Positive Lymphoma$
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-Positive LymphomaDecember 7th, 2020
$Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma$
Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell LymphomaNovember 9th, 2019
Affimed Reports Financial Results for Third Quarter 2018 and Operational ProgressNovember 7th, 2018